ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 050,52
-0,18%
Dow Jones
38 386,09
0,38%
DAX
18 045,85
-0,47%
Brent Oil
87,39
0,12%
Bitcoin
61 704,74
-3,34%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Ovid Therapeutics Inc (OVID)

  7. Ovid Therapeutics Inc (OVID) Actualités

OVID Ovid Therapeutics Inc

3,34
0,00 (0,00%)
Avant marché
Dernière mise à jour : 12:04:21
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Ovid Therapeutics Inc OVID NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 3,34 12:04:21
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
3,34
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
04/4/202414:00GLOBEOvid Therapeutics to Present at the 23rd Annual Needham..
08/3/202414:24EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
08/3/202414:20EDGAR2Form 8-K - Current report
08/3/202414:00GLOBEOvid Therapeutics Reports Business Updates, Fourth Quarter..
28/2/202414:00GLOBEOvid Therapeutics to Present at the TD Cowen 44th Annual..
27/2/202400:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202400:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202423:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202423:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202417:10EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202412:06EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202414:00GLOBEOvid Therapeutics to Present at the Oppenheimer 34th Annual..
06/12/202323:08EDGAR2Form 8-K - Current report
01/12/202313:30GLOBEOvid Therapeutics to Present Five Abstracts Supporting its..
16/11/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
15/11/202322:11EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
03/11/202321:08EDGAR2Form S-3 - Registration statement under Securities Act of..
03/11/202313:13EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/11/202313:10EDGAR2Form 8-K - Current report
03/11/202313:00GLOBEOvid Therapeutics Reports Third Quarter 2023 Financial..
18/10/202314:04EDGAR2Form 8-K - Current report
18/10/202314:00GLOBEOvid Therapeutics and Ligand Pharmaceuticals Enter into a..
10/10/202314:00GLOBEOvid Therapeutics to Present at the Jefferies Biotech..
02/10/202318:15EDGAR2Form 8-K - Current report
26/9/202313:30GLOBEOvid Therapeutics to Host Investor Event - R&D Day on..
20/9/202313:30GLOBEOvid Therapeutics to Present at the 2023 Cantor Fitzgerald..
30/8/202314:00GLOBEOvid Therapeutics to Participate in Upcoming September..
04/8/202315:23EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
04/8/202315:10EDGAR2Form 8-K - Current report
04/8/202314:00GLOBEOvid Therapeutics Reports Second Quarter 2023 Financial..
01/8/202314:00GLOBEOvid Therapeutics to Present at the BTIG Virtual..
31/7/202323:21EDGAR2Form SC 13G - Statement of acquisition of beneficial..
28/6/202314:00GLOBEOvid Therapeutics Expands Its Scientific Leadership Team &..
26/6/202314:00GLOBEOvid Therapeutics Added to Russell 3000® Index
05/5/202313:30GLOBEOvid Therapeutics Reports First Quarter 2023 Financial..
01/5/202312:00GLOBEOvid Therapeutics Announces Collaboration with Graviton..

Dernières Valeurs Consultées

NASDAQ
OVID
Ovid Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés